All Trials

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors; dose escalation includes refractory/metastatic tumors (notably malignant mesothelioma and epithelioid hemangioendothelioma), with expansion for mesothelioma, EHE regardless of Hippo status, and other tumors harboring Hippo pathway alterations. Patients receive oral BGC515, a covalent pan‑TEAD1–4 inhibitor targeting the Hippo/YAP–TAZ transcriptional pathway, once daily in 21‑day cycles.

ClinicalTrials.gov ID: NCT06452160

Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children and young adults with relapsed/refractory pediatric-type solid tumors (non-CNS) receive cyclophosphamide/etoposide lymphodepletion followed by a single infusion of ex vivo expanded, cord blood–derived allogeneic NK cells (4–6/6 HLA-matched donor). The NK cells are activated to enhance MHC-unrestricted cytotoxicity (via natural cytotoxicity receptors and ADCC) to assess safety, dosing, persistence, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT03420963

A Phase 1, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced/metastatic malignant mesothelioma (post–platinum and checkpoint inhibitor) or other solid tumors, with Part 2 requiring documented Hippo pathway dysregulation for non-mesothelioma, receive once-daily oral ISM6331 monotherapy. ISM6331 is a small‑molecule, non‑covalent pan‑TEAD (TEAD1–4) inhibitor targeting the TEAD palmitoylation pocket to suppress YAP/TAZ–TEAD transcription in Hippo-dysregulated tumors.

ClinicalTrials.gov ID: NCT06566079

A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors after standard therapy, enriched for mesothelioma and cancers with Hippo pathway alterations (e.g., NF2, LATS1/2, FAT1, YAP/TAZ fusions), receive continuous oral SW-682. SW-682 is a selective pan‑TEAD inhibitor targeting the TEAD palmitoylation pocket to disrupt YAP/TAZ‑TEAD transcription; dose-escalation/expansion includes histology/genomic cohorts and a planned combination-therapy cohort.

ClinicalTrials.gov ID: NCT06251310

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults and adolescents (16–80 years) with CD70-positive advanced clear cell RCC (post PD-1/PD-L1 and anti-angiogenic therapy), mesothelioma (progressive after standard options including checkpoint blockade), or osteosarcoma (recurrent/refractory after anthracycline) receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of allogeneic cord blood–derived CAR NK cells targeting CD70 via a CD27-based CAR, armored with IL-15 for persistence and containing an inducible caspase-9 safety switch. Single-arm dose-escalation/expansion evaluates safety, dose, persistence, and preliminary activity.

ClinicalTrials.gov ID: NCT05703854

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable, advanced solid tumors harboring confirmed RAS mutations (KRAS/NRAS/HRAS), ECOG 0–1, and measurable disease receive RO7673396 (RG6505), an investigational small‑molecule RAS‑pathway inhibitor with potential pan‑RAS activity, as monotherapy in dose escalation and expansion. Excludes active/untreated CNS metastases and significant GI/liver issues; endpoints include safety, DLTs, PK, and preliminary efficacy (ORR by RECIST).

ClinicalTrials.gov ID: NCT06884618

Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children, adolescents, and young adults (12 months–50 years) with high-risk, recurrent, or refractory sarcomas (and select poor-prognosis solid tumors) who are ≥day +120 after reduced-intensity haploidentical bone marrow transplant with PTCy receive post-transplant nivolumab. Nivolumab is a PD-1–blocking monoclonal antibody given IV (weight/flat dosing) for up to 24 cycles to enhance donor T‑cell antitumor activity while monitoring for GVHD and immune-related toxicities.

ClinicalTrials.gov ID: NCT03465592

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Pediatric, adolescent, and young adult patients (1–25 years) with recurrent/progressive HER2‑positive sarcoma (≥1+ by IHC) after prior systemic therapy receive autologous HER2‑targeted second‑generation (CD28ζ) CAR T cells after cyclophosphamide/fludarabine lymphodepletion, followed about a week later by PD‑1 blockade with pembrolizumab (q3w) or nivolumab (q2w), with option for repeat CAR T infusions. Excludes significant autoimmune disease, active infection, bulky disease, prior severe Cy/Flu or checkpoint reactions, and major cardiopulmonary contraindications.

ClinicalTrials.gov ID: NCT04995003

A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and either advanced, unresectable/metastatic soft tissue sarcoma after at least one prior metastatic-line (including anthracycline) or IDH‑wildtype glioblastoma after first-line chemoradiation are eligible. Investigational therapy is M3554, an anti‑GD2 antibody–drug conjugate delivering the topoisomerase I inhibitor exatecan via a cleavable linker, given as monotherapy in dose escalation/expansion.

ClinicalTrials.gov ID: NCT06641908

A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory locally advanced/metastatic TP53 (p53) wild-type solid tumors (Phase 1 also allows relapsed/refractory non-Hodgkin lymphoma) receive SA53-OS, an oral small-molecule MDM2 inhibitor designed to reactivate wild-type p53. Phase 2a expands to dedifferentiated liposarcoma with MDM2 amplification and other TP53 wild-type solid tumors, with SA53-OS given 3 days every 3 weeks at the RP2D.

ClinicalTrials.gov ID: NCT06578624